Title (en)

FATTY ACID AMIDE HYDROLASE INHIBITORS

Title (de)

INHIBITOREN VON FETTSÄUREAMIDHYDROLASE

Title (fr)

INHIBITEURS D'AMIDE D'ACIDE GRAS HYDROLASE

Publication

EP 2051964 A2 20090429 (EN)

Application

EP 07797050 A 20070727

Priority

- US 2007016953 W 20070727
- US 83393706 P 20060728

Abstract (en)

[origin: WO2008013963A2] Disclosed are compounds of formula R-X-Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CBl and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.

IPC 8 full level

C07D 213/02 (2006.01); **A61K 31/4245** (2006.01); **A61K 31/425** (2006.01); **A61K 31/44** (2006.01); **C07C 233/02** (2006.01); **C07D 271/06** (2006.01); **C07D 277/02** (2006.01)

CPC (source: EP US)

C07C 17/16 (2013.01 - EP US); **C07C 45/41** (2013.01 - EP US); **C07C 45/44** (2013.01 - EP US); **C07C 45/45** (2013.01 - EP US); **C07C 45/673** (2013.01 - EP US); **C07C 49/233** (2013.01 - EP US); **C07C 49/255** (2013.01 - EP US); **C07C 49/84** (2013.01 - EP US); **C07C 69/712** (2013.01 - EP US); **C07C 69/738** (2013.01 - EP US); **C07C 271/12** (2013.01 - EP US); **C07C 271/14** (2013.01 - EP US); **C07C 271/16** (2013.01 - EP US); **C07C 271/24** (2013.01 - EP US); **C07C 271/38** (2013.01 - EP US); **C07C 271/58** (2013.01 - EP US); **C07C 309/68** (2013.01 - EP US); **C07C 309/81** (2013.01 - EP US); **C07C 309/82** (2013.01 - EP US); **C07D 213/30** (2013.01 - EP US); **C07D 213/40** (2013.01 - EP US); **C07D 213/50** (2013.01 - EP US); **C07D 213/75** (2013.01 - EP US); **C07D 263/56** (2013.01 - EP US); **C07D 271/10** (2013.01 - EP US); **C07D 275/06** (2013.01 - EP US); **C07D 277/64** (2013.01 - EP US); C07C 2601/14 (2017.04 - EP US); C07C 2603/74 (2017.04 - EP US)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2008013963 A2 20080131; **WO 2008013963 A3 20081127**; CA 2658887 A1 20080131; CA 2658887 C 20160823; EP 2051964 A2 20090429; EP 2051964 A4 20120307; US 2009306016 A1 20091210; US 9102622 B2 20150811

DOCDB simple family (application)

US 2007016953 W 20070727; CA 2658887 A 20070727; EP 07797050 A 20070727; US 30966107 A 20070727